TY - JOUR
T1 - Dihydrophenanthropyrans derived from the pseudobulbs of Pholidota chinensis alleviates neutrophilic inflammation by inhibiting MAPKs and calcium
AU - Chen, Yu Cheng
AU - Pan, Wen Xuan
AU - Wang, Yi Hsuan
AU - Tsai, Cheng Ming
AU - Hwang, Tsong Long
AU - Lam, Sio Hong
N1 - Copyright © 2024 Elsevier B.V. All rights reserved.
PY - 2024/7
Y1 - 2024/7
N2 - Five dihydrophenanthropyrans (1–5) were isolated from the pseudobulbs of Pholidota chinensis, among which 1,3-di(4′-hydroxybenzy)-imbricatin (3) was isolated from the nature for the first time. Their structures were elucidated and established through various spectroscopic methods. These compounds exhibited a potent inhibition effect on both N-formyl-methionyl-leucyl-phenylalanine (fMLF)-induced superoxide anion generation and elastase release with IC50 values ranging from 0.23 to 7.63 μM. Furthermore, dihydrophenanthropyrans (1–3) also demonstrated a dose-dependent reactive oxygen species (ROS) scavenging effect. In addition, dihydrophenanthropyrans (2–3) exhibited a dose-dependent reduction in the intracellular Ca2+ concentration ([Ca2+]i) in fMLF-activated human neutrophils. Moreover, dihydrophenanthropyrans (1–3) selectively inhibited the phosphorylation of c-Jun N-terminal kinases (JNKs) and p38, while only dihydrophenanthropyran (1) inhibited the phosphorylation of extracellular signal-regulated kinases (ERKs) in fMLF-activated human neutrophils. Notably, dihydrophenanthropyrans (1–3) did not affect protein kinase B (AKT) activity in these cells. These findings highlight the potent anti-inflammatory capabilities of dihydrophenanthropyrans, manifested through their ability to inhibit superoxide anion generation, suppress elastase release, and selectively modulate key signaling pathways in human neutrophils. This suggests that dihydrophenanthropyrans hold significant promise as therapeutic agents for conditions associated with neutrophil-mediated inflammation.
AB - Five dihydrophenanthropyrans (1–5) were isolated from the pseudobulbs of Pholidota chinensis, among which 1,3-di(4′-hydroxybenzy)-imbricatin (3) was isolated from the nature for the first time. Their structures were elucidated and established through various spectroscopic methods. These compounds exhibited a potent inhibition effect on both N-formyl-methionyl-leucyl-phenylalanine (fMLF)-induced superoxide anion generation and elastase release with IC50 values ranging from 0.23 to 7.63 μM. Furthermore, dihydrophenanthropyrans (1–3) also demonstrated a dose-dependent reactive oxygen species (ROS) scavenging effect. In addition, dihydrophenanthropyrans (2–3) exhibited a dose-dependent reduction in the intracellular Ca2+ concentration ([Ca2+]i) in fMLF-activated human neutrophils. Moreover, dihydrophenanthropyrans (1–3) selectively inhibited the phosphorylation of c-Jun N-terminal kinases (JNKs) and p38, while only dihydrophenanthropyran (1) inhibited the phosphorylation of extracellular signal-regulated kinases (ERKs) in fMLF-activated human neutrophils. Notably, dihydrophenanthropyrans (1–3) did not affect protein kinase B (AKT) activity in these cells. These findings highlight the potent anti-inflammatory capabilities of dihydrophenanthropyrans, manifested through their ability to inhibit superoxide anion generation, suppress elastase release, and selectively modulate key signaling pathways in human neutrophils. This suggests that dihydrophenanthropyrans hold significant promise as therapeutic agents for conditions associated with neutrophil-mediated inflammation.
KW - Anti-inflammation
KW - Dihydrophenanthropyrans
KW - Human neutrophils
KW - Orchidaceae
KW - Reactive Oxygen Species/metabolism
KW - Humans
KW - JNK Mitogen-Activated Protein Kinases/metabolism
KW - Anti-Inflammatory Agents/pharmacology
KW - Orchidaceae/chemistry
KW - Calcium/metabolism
KW - Neutrophils/drug effects
KW - Superoxides/metabolism
KW - Mitogen-Activated Protein Kinases/metabolism
KW - China
KW - Phytochemicals/pharmacology
KW - Molecular Structure
KW - Inflammation/drug therapy
KW - Pancreatic Elastase/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85193502650&partnerID=8YFLogxK
U2 - 10.1016/j.fitote.2024.106015
DO - 10.1016/j.fitote.2024.106015
M3 - 文章
C2 - 38762075
AN - SCOPUS:85193502650
SN - 0367-326X
VL - 176
SP - 106015
JO - Fitoterapia
JF - Fitoterapia
M1 - 106015
ER -